Broad nucleoside reverse-transcriptase inhibitor cross-resistance in human immunodeficiency virus type 1 clinical isolates.

Nucleoside reverse-transcriptase inhibitors (NRTIs) are important components of most antiretroviral combination treatment regimens. Using a large collection of clinical isolates, we characterized patterns of cross-resistance among all NRTIs. Drugs were grouped by the effect of the M184V mutation: susceptibility to group 1 drugs (zidovudine, stavudine, tenofovir, and adefovir) increased when M184V was present, whereas susceptibility to group 2 drugs (didanosine, zalcitabine, abacavir, and lamivudine) decreased. Significant cross-resistance was observed among all NRTIs and was most notable when samples with or without M184V were analyzed separately. An increasing number of thymidine-analogue mutations (TAMs) was associated with a progressive reduction in drug susceptibility for all NRTIs. The modulating effect of M184I/V on drug susceptibility was present regardless of the number of TAMs. The broad range of susceptibility observed for viruses containing the same number of TAMs indicates that the genetic correlates of NRTI resistance remain to be fully elucidated.

[1]  E. De Clercq,et al.  Prevalence and Characteristics of Multinucleoside-Resistant Human Immunodeficiency Virus Type 1 among European Patients Receiving Combinations of Nucleoside Analogues , 2000, Antimicrobial Agents and Chemotherapy.

[2]  P. Harrigan,et al.  Significance of amino acid variation at human immunodeficiency virus type 1 reverse transcriptase residue 210 for zidovudine susceptibility , 1996, Journal of virology.

[3]  K. Hertogs,et al.  Correlation of Phenotypic Zidovudine Resistance with Mutational Patterns in the Reverse Transcriptase of Human Immunodeficiency Virus Type 1: Interpretation of Established Mutations and Characterization of New Polymorphisms at Codons 208, 211, and 214 , 2003, Antimicrobial Agents and Chemotherapy.

[4]  D. Stuart,et al.  A Family of Insertion Mutations between Codons 67 and 70 of Human Immunodeficiency Virus Type 1 Reverse Transcriptase Confer Multinucleoside Analog Resistance , 1999, Antimicrobial Agents and Chemotherapy.

[5]  M. Hillebrand,et al.  Insertion of two amino acids combined with changes in reverse transcriptase containing tyrosine-215 of HIV-1 resistant to multiple nucleoside analogs. , 1999, AIDS.

[6]  B. Larder.  3'-Azido-3'-deoxythymidine resistance suppressed by a mutation conferring human immunodeficiency virus type 1 resistance to nonnucleoside reverse transcriptase inhibitors , 1992, Antimicrobial Agents and Chemotherapy.

[7]  John W. Mellors,et al.  A Novel Polymorphism at Codon 333 of Human Immunodeficiency Virus Type 1 Reverse Transcriptase Can Facilitate Dual Resistance to Zidovudine and l-2′,3′-Dideoxy-3′-Thiacytidine , 1998, Journal of Virology.

[8]  D. Katzenstein,et al.  A 6-basepair insert in the reverse transcriptase gene of human immunodeficiency virus type 1 confers resistance to multiple nucleoside inhibitors. , 1998, The Journal of clinical investigation.

[9]  D. Katzenstein,et al.  Subtle decreases in stavudine phenotypic susceptibility predict poor virologic response to stavudine monotherapy in zidovudine-experienced patients. , 2002, Journal of acquired immune deficiency syndromes.

[10]  E. De Clercq,et al.  Multiple drug resistance to nucleoside analogues and nonnucleoside reverse transcriptase inhibitors in an efficiently replicating human immunodeficiency virus type 1 patient strain. , 1996, The Journal of infectious diseases.

[11]  Michael S Saag,et al.  Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. , 2002, JAMA.

[12]  C. Petropoulos,et al.  Phenotypic and genotypic HIV-1 drug resistance assays provide complementary information. , 2002, Journal of acquired immune deficiency syndromes.

[13]  B. Larder,et al.  Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[14]  Tom de Groot,et al.  Lamivudine-resistant human immunodeficiency virus type 1 variants (184V) require multiple amino acid changes to become co-resistant to zidovudine in vivo. , 1997, The Journal of infectious diseases.

[15]  Samantha MaWhinney,et al.  Phenotypic and Genotypic Analysis of Biologically Cloned Human Immunodeficiency Virus Type 1 Isolates from Patients Treated with Zidovudine and Lamivudine , 2002, Antimicrobial Agents and Chemotherapy.

[16]  D. Katzenstein,et al.  Combination therapy with zidovudine and didanosine selects for drug-resistant human immunodeficiency virus type 1 strains with unique patterns of pol gene mutations. , 1994, The Journal of infectious diseases.

[17]  E. De Clercq,et al.  Evolution of HIV drug Resistance in Zidovudine/Zalcitabine- and Zidovudine/ Didanosine-Experienced Patients Receiving Lamivudine-Containing Combination Therapy , 1998 .

[18]  D. Richman.  Antiretroviral drug resistance: mechanisms, pathogenesis, clinical significance. , 1996, Advances in experimental medicine and biology.

[19]  E A Emini,et al.  Susceptibilities of human immunodeficiency virus type 1 enzyme and viral variants expressing multiple resistance-engendering amino acid substitutions to reserve transcriptase inhibitors , 1994, Antimicrobial Agents and Chemotherapy.

[20]  K. Hertogs,et al.  A Novel Human Immunodeficiency Virus Type 1 Reverse Transcriptase Mutational Pattern Confers Phenotypic Lamivudine Resistance in the Absence of Mutation 184V , 2000, Antimicrobial Agents and Chemotherapy.

[21]  G. Satten,et al.  Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. , 1998, The New England journal of medicine.

[22]  D. Kempf,et al.  Analysis of the Virological Response with Respect to Baseline Viral Phenotype and Genotype in Protease Inhibitor-Experienced HIV-1-Infected Patients Receiving Lopinavir/Ritonavir Therapy , 2001, Antiviral therapy.

[23]  M. Wainberg,et al.  In vitro Selection and Characterization of HIV-1 with Reduced Susceptibility to PMPA , 1998, Antiviral therapy.

[24]  M. Wainberg,et al.  High-level resistance to (-) enantiomeric 2'-deoxy-3'-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptase , 1993, Antimicrobial Agents and Chemotherapy.

[25]  C. Petropoulos,et al.  Improving lopinavir genotype algorithm through phenotype correlations: novel mutation patterns and amprenavir cross-resistance , 2003, AIDS.

[26]  P. Kissinger,et al.  Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. , 1998, The New England journal of medicine.

[27]  V. Calvez,et al.  Genotypic and Phenotypic Resistance Patterns of Human Immunodeficiency Virus Type 1 Variants with Insertions or Deletions in the Reverse Transcriptase (RT): Multicenter Study of Patients Treated with RT Inhibitors , 2001, Antimicrobial Agents and Chemotherapy.

[28]  B. Larder,et al.  Mutational Patterns in the HIV Genome and Cross-Resistance following Nucleoside and Nucleotide Analogue Drug Exposure , 2000, Antiviral therapy.

[29]  S D Kemp,et al.  Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[30]  S. Hammer,et al.  Phenotypic and genotypic resistance patterns of HIV-1 isolates derived from individuals treated with didanosine and stavudine , 2000, AIDS.

[31]  Christos J. Petropoulos,et al.  A Novel Phenotypic Drug Susceptibility Assay for Human Immunodeficiency Virus Type 1 , 2000, Antimicrobial Agents and Chemotherapy.

[32]  J. Mellors,et al.  In Vitro Selection of Mutations in the Human Immunodeficiency Virus Type 1 Reverse Transcriptase That Decrease Susceptibility to (−)-β-d-Dioxolane-Guanosine and Suppress Resistance to 3′-Azido-3′-Deoxythymidine , 2000, Antimicrobial Agents and Chemotherapy.

[33]  Lee Bacheler,et al.  Phenotypic susceptibility and virological outcome in nucleoside-experienced patients receiving three or four antiretroviral drugs , 2003, AIDS.

[34]  E. Arnold,et al.  An in vivo mutation from leucine to tryptophan at position 210 in human immunodeficiency virus type 1 reverse transcriptase contributes to high-level resistance to 3'-azido-3'-deoxythymidine , 1996, Journal of virology.

[35]  D. Kuritzkes,et al.  Drug resistance and virologic response in NUCA 3001, a randomized trial of lamivudine (3TC) versus zidovudine (ZDV) versus ZDV plus 3TC in previously untreated patients , 1996, AIDS.

[36]  R. Schooley,et al.  Genotypic and phenotypic analyses of HIV-1 in antiretroviral-experienced patients treated with tenofovir DF , 2002, AIDS.

[37]  S D Kemp,et al.  Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. , 1995, Science.

[38]  S D Kemp,et al.  Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). , 1989, Science.

[39]  B. Larder,et al.  Broad nucleoside-analogue resistance implications for human immunodeficiency virus type 1 reverse-transcriptase mutations at codons 44 and 118. , 2002, The Journal of infectious diseases.